Docetaxel Does Not Compromise Long-Term QOL in Men with Metastatic Hormone-Sensitive Prostate Cancer
Docetaxel added to androgen-deprivation therapy (ADT) improves survival for men with metastatic hormone-sensitive prostate cancer (mHSPC), as shown by the pivotal ECOG 3805 CHAARTED trial.
Active Holistic Surveillance Incorporates Diet, Supplements, Exercise for Low-Risk and Low-Intermediate–Risk Prostate Cancer
Men with low-risk prostate cancer are typically offered management with active surveillance, which entails regular office visits, digital rectal exam, MRI scans, prostate-specific antigen (PSA) testing, and prostate biopsy at physician-specified intervals.
Second-Line Treatment with Ramucirumab After First-Line Sorafenib for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma is the second most common cause of cancer-related death and occurs most often in patients with cirrhosis. Vascular endothelial growth factor (VEGF) plays an important role in tumor growth and angiogenesis, and is overexpressed in patients with hepatocellular carcinoma.
Two pilot programs have shown success in raising awareness of safety concerns aimed at reducing the utilization of inappropriate testosterone replacement therapy.
Two pilot programs aimed at reducing the utilization of inappropriate testosterone replacement therapy, particularly in the treatment of men with age-related hypogonadism, have shown success in raising awareness of evidence and safety concerns.
Although recent studies have shown the efficacy of using stereotactic body radiation therapy (SBRT) as a treatment modality for organ-confined prostate cancer, questions over urinary symptoms and sexual dysfunction have remained.
Sunitinib and pazopanib have long battled for supremacy in treating advanced renal-cell carcinoma (RCC). According to findings presented at the National Comprehensive Cancer Network 20th Annual Conference, the newer drug, pazopanib, may have some benefit in total cost of care; survival outcomes were the same between drugs.
Although recent studies have shown the efficacy of using stereotactic body radiation therapy (SBRT) as a treatment modality for organ-confined prostate cancer, questions over urinary symptoms and sexual dysfunction have remained. According to findings presented at the 2015 Genitourinary Cancers Symposium, those questions have been answered: the SBRT approach demonstrates acceptable urinary and sexual toxicity.
Use of adjuvant sorafenib and sunitinib failed to extend disease-free survival (DFS) in patients with locally advanced kidney cancer at high risk of recurrence, according to initial results from the ASSURE study presented at the 2015 Genitourinary Cancers Symposium. ASSURE is the first and largest study of adjuvant vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors in kidney cancer.
Experts are hopeful that the field of prostate cancer will soon be catching up to breast cancer and some other tumor types with regard to genomic markers. A study featured at the 2015 Genitourinary Cancers Symposium suggests that the androgen receptor (AR) abnormality known as AR-V7 will turn out to be a predictive marker to help in treatment selection for patients with metastatic castration-resistant prostate cancer (CRPC).
Page 3 of 9
Results 21 - 30 of 88
Results 21 - 30 of 88